Does Mounjaro Contain a GLP-1 Agonist? The Dual-Receptor Answer

Step 1: what GLP-1 actually does in the body

GLP-1 is a hormone released naturally from the gut after eating. It signals to the brain that food has arrived, slows the rate at which the stomach empties, and prompts the pancreas to produce insulin in proportion to blood-glucose levels. A GLP-1 receptor agonist mimics this signal pharmacologically, keeping it active for longer than the body's own brief burst would allow.

For weight management, the relevant effect is appetite regulation. When GLP-1 receptors are activated consistently, people typically feel full sooner and stay full longer between meals. The NHS medicines page for tirzepatide describes this mechanism clearly for patients, and it is the same pathway that semaglutide uses as a single-agonist. So yes, Mounjaro does contain GLP-1 receptor activity. But that is only half the picture.

Worth being precise here: if you are curious about whether Mounjaro contains insulin, the short answer is no, it contains tirzepatide, a synthetic molecule engineered to bind to and activate GLP-1 receptors (alongside GIP receptors). If you want a full breakdown of every ingredient, our page covering what Mounjaro contains goes through the active and inactive components in detail, and our page on which medicines and products contain tirzepatide covers those components further.

Step 2: where GIP adds a second layer

Glucose-dependent insulinotropic polypeptide, GIP, is the less-discussed partner. It is also a gut hormone released after eating, and it plays a role in fat storage, energy balance, and insulin secretion. Tirzepatide was engineered to bind both receptors with roughly equal affinity, which is why its clinical results differ from those of GLP-1-only medicines.

In the SURMOUNT-1 trial, published in the New England Journal of Medicine, participants taking tirzepatide 15mg lost an average of around 20–21% of their body weight over 72 weeks. That figure is higher than what single-agonist GLP-1 medicines produced in comparable trials. The SURMOUNT-5 head-to-head study confirmed the pattern directly: tirzepatide produced greater average weight loss than semaglutide 2.4mg in a 72-week trial. Researchers attribute part of that difference to GIP's additional contribution, though the full picture of why dual agonism outperforms single agonism is still being studied.

If you are comparing Mounjaro to other treatments, the page on how Mounjaro works as a GLP-1 and GIP dual agonist sets out those differences in plain terms.

Step 3: what dual-agonist status means for you practically

The practical upshot is that Mounjaro and a single-agonist GLP-1 medicine like semaglutide are not interchangeable, even though both act on GLP-1 receptors. They have different molecular structures, different receptor profiles, and different titration schedules. A prescriber choosing between them considers your medical history, any existing conditions, medicines you already take, and your tolerance of GI side effects, not just the results data.

Common side effects across both classes are GI-led: nausea, loose stools, constipation, and indigestion are most frequently reported, particularly in the early weeks or after a dose increase. These are real, though for most people they settle. Rarely, more serious effects occur; the MHRA has highlighted acute pancreatitis as an infrequent but potentially serious risk with GLP-1 medicines, and anyone experiencing severe, persistent stomach pain radiating to the back should seek medical attention promptly and report it at the MHRA Yellow Card scheme.

Mounjaro is not suitable during pregnancy, while breastfeeding, or for anyone under 18. People trying to conceive should discuss the appropriate wash-out period with their prescriber before stopping treatment. Oral contraceptive pill users starting tirzepatide should add a non-oral method for the first four weeks of treatment and after each dose increase, because gastric-emptying changes may reduce pill absorption, a detail that surprises many people and that a prescriber will walk you through at consultation.

On cost, private treatment pricing varies by dose and provider. If you are weighing up what a private prescription actually includes, the Mounjaro pricing context page explains what market rates typically look like and what a transparent, all-in service covers. Eligibility criteria for NHS access to tirzepatide are phased and currently strict; for many people, a private route through a regulated online pharmacy is the practical option.

Step 4: verifying you are getting genuine tirzepatide

Because tirzepatide's dual mechanism is clinically specific, its supply must come through the licensed UK supply chain. Counterfeit pens sold online have, in documented MHRA cases, contained entirely different substances. A legitimate supply requires a valid prescription following a clinical assessment, any seller offering these medicines without one is a serious red flag, and suspect sellers can be reported through the Yellow Card scheme.

At nume, sorry, at nume, every order is reviewed the same day by a real GPhC-registered prescriber, not software. The pharmacy holds GPhC premises registration 9012878, verifiable directly on the GPhC register. Medicines arrive from the authorised UK supply chain via Eli Lilly's licensed routes. For a fuller picture of tirzepatide as a treatment, the tirzepatide overview covers the clinical programme, dosing schedule, and what to expect. And if you want to explore whether you might be suitable, check your eligibility with our prescribers, the consultation is free.